Nuveen Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.2M | Sell |
147,523
-6,851
| -4% | -$55.6K | ﹤0.01% | 2633 |
|
|
2024
Q3 | $2.79M | Buy |
154,374
+13,352
| +9% | +$241K | ﹤0.01% | 2261 |
|
|
2024
Q2 | $1.45M | Sell |
141,022
-121,026
| -46% | -$1.25M | ﹤0.01% | 2541 |
|
|
2024
Q1 | $2.78M | Sell |
262,048
-42,561
| -14% | -$452K | ﹤0.01% | 2249 |
|
|
2023
Q4 | $2.78M | Buy |
304,609
+16,775
| +6% | +$153K | ﹤0.01% | 2258 |
|
|
2023
Q3 | $2.98M | Buy |
287,834
+106,225
| +58% | +$1.1M | ﹤0.01% | 2125 |
|
|
2023
Q2 | $2.6M | Buy |
181,609
+73,325
| +68% | +$1.05M | ﹤0.01% | 2225 |
|
|
2023
Q1 | $773K | Buy |
108,284
+357
| +0.3% | +$2.55K | ﹤0.01% | 2696 |
|
|
2022
Q4 | $1.21M | Sell |
107,927
-9,652
| -8% | -$108K | ﹤0.01% | 2612 |
|
|
2022
Q3 | $1.3M | Buy |
117,579
+2,036
| +2% | +$22.6K | ﹤0.01% | 2616 |
|
|
2022
Q2 | $976K | Buy |
115,543
+53,962
| +88% | +$456K | ﹤0.01% | 2789 |
|
|
2022
Q1 | $823K | Buy |
61,581
+1,363
| +2% | +$18.2K | ﹤0.01% | 2876 |
|
|
2021
Q4 | $1.18M | Sell |
60,218
-9,377
| -13% | -$184K | ﹤0.01% | 2798 |
|
|
2021
Q3 | $2.23M | Sell |
69,595
-24,490
| -26% | -$786K | ﹤0.01% | 2618 |
|
|
2021
Q2 | $3.19M | Buy |
94,085
+28,129
| +43% | +$952K | ﹤0.01% | 2485 |
|
|
2021
Q1 | $2.48M | Buy |
65,956
+2,950
| +5% | +$111K | ﹤0.01% | 2518 |
|
|
2020
Q4 | $2.09M | Buy |
63,006
+1,335
| +2% | +$44.3K | ﹤0.01% | 2487 |
|
|
2020
Q3 | $2.26M | Buy |
61,671
+11,633
| +23% | +$427K | ﹤0.01% | 2319 |
|
|
2020
Q2 | $1.65M | Buy |
50,038
+14,546
| +41% | +$479K | ﹤0.01% | 2418 |
|
|
2020
Q1 | $917K | Buy |
35,492
+147
| +0.4% | +$3.8K | ﹤0.01% | 2550 |
|
|
2019
Q4 | $1.1M | Buy |
+35,345
| New | +$1.1M | ﹤0.01% | 2654 |
|